The Clinical Investigations Core Shared Resource (CICSRSR) supports the """"""""develop"""""""" portion of the broader UCCC mission to discover, develop and deliver breakthroughs in diagnosis, treatment, and prevention that improve cancer care. Services and Personnel: This CICSRSR objective is accomplished by providing the necessary infrastructure quality and quantity to deliver exceptional cancer clinical trials research support across the UCCC consortium including: 1) Support of all aspects of clinical investigations including patient recruitment and treatment, collection of data, procurement of specimens, reporting of adverse events and coordination of care with other clinical services;2) Performance of all aspects of regulatory compliance, IRB submission and quality assurance;3) Ensuring fiscal and operational excellence leading to cost effectiveness;4) Deployment of these facilities to outreach sites throughout Colorado and Wyoming. Leadership of >100 CICSRSR staff is provided by a Medical Director, Executive Director, Regulatory Affairs Manager, Financial Manager and Disease Site Team Leaders. The disease site teams of the CICSRSR are located on the 3rd floor of the Anschutz Cancer Pavilion. This places those individuals who interact directly with the patients and physicians in close proximity to both, thereby facilitating the trial enrollment process. Education and Training: The CICSRSR provides clinical trial education to investigators, research staff and clinic personnel via seminars and forums and has leveraged the educational facilities of our CTSA to do this cost effectively. Utilization: In 2010 CICSRSR provided service to 79 members from all UCCC Scientific Programs in support of 515 active (Investigator-initiated: 167;cooperative group: 198) clinical trials. A total of 9,911 subjects (1,112 to intervention and 8,799 to non-intervention) were accrued, a 55% increase since 2005. Therapeutic enrollments totaled 1,044, a 75% increase in the same period and represent 27% of newly registered cancer patients in the UCCC consortium and affiliate sites. Management and Finances: This resource is UCCC-managed. Currently, 2% of the operating budget comes from CCSG support and 40% from charge backs. CICSRSR requests $586,909 of CCSG support for 5% of its projected operating budget for the renewal period. Future directions: In the next funding period, we have plans to: 1) Lower barriers for investigator initiated trials by developing a novel Protocol Development Pathway;2) Expedite protocol opening timelines by implementing findings from an ARRA grant we obtained in 2009;and 3) Expand operational support to outreach sites by enhanced telecommunication.
The Clinical Investigations Core Shared Resource (CICSRSR) provides support to clinical investigators on all activities related to the successful conduct of clinical trial research. This is the cornerstone to translate basic science knowledge of the cancer process into clinically useful treatments for patients.
|Giles, Erin D; Jindal, Sonali; Wellberg, Elizabeth A et al. (2018) Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res 20:50|
|Nemkov, Travis; Sun, Kaiqi; Reisz, Julie A et al. (2018) Hypoxia modulates the purine salvage pathway and decreases red blood cell and supernatant levels of hypoxanthine during refrigerated storage. Haematologica 103:361-372|
|Soontararak, Sirikul; Chow, Lyndah; Johnson, Valerie et al. (2018) Mesenchymal Stem Cells (MSC) Derived from Induced Pluripotent Stem Cells (iPSC) Equivalent to Adipose-Derived MSC in Promoting Intestinal Healing and Microbiome Normalization in Mouse Inflammatory Bowel Disease Model. Stem Cells Transl Med 7:456-467|
|Shearn, Colin T; Pulliam, Casey F; Pedersen, Kim et al. (2018) Knockout of the Gsta4 Gene in Male Mice Leads to an Altered Pattern of Hepatic Protein Carbonylation and Enhanced Inflammation Following Chronic Consumption of an Ethanol Diet. Alcohol Clin Exp Res 42:1192-1205|
|Ross, Brian C; Boguslav, Mayla; Weeks, Holly et al. (2018) Simulating heterogeneous populations using Boolean models. BMC Syst Biol 12:64|
|Wang, Guankui; Benasutti, Halli; Jones, Jessica F et al. (2018) Isolation of Breast cancer CTCs with multitargeted buoyant immunomicrobubbles. Colloids Surf B Biointerfaces 161:200-209|
|Suda, Kenichi; Kim, Jihye; Murakami, Isao et al. (2018) Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. J Thorac Oncol 13:1496-1507|
|Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98|
|Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550|
|Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122|
Showing the most recent 10 out of 1634 publications